27561345|t|Teriparatide: benefit and safety for bone disease in CKD patients undergoing hemodialysis
27561345|a|Teriparatide, 1-34 parathyroid hormone, is one of effective treatments for osteoporosis. Teriparatide shows an anabolic effect for bone formation, as a result, increases bone mineral density as well as prevention of fractures in the general population. On the other hand, there are a few report about the effect of teriparatide on increase of bone mineral density in maintenance hemodialysis patients. In addition to CKD-MBD, osteoporosis is also an important pathological change in ESRD patients, therefore its safety and efficacy should be discussed in more detail.
27561345	0	12	Teriparatide	T116,T121,T125	C0070093
27561345	14	21	benefit	T081	C0814225
27561345	26	32	safety	T080	C0205556
27561345	37	49	bone disease	T047	C0005940
27561345	53	56	CKD	T047	C1561643
27561345	57	65	patients	T101	C0030705
27561345	77	89	hemodialysis	T061	C0019004
27561345	90	102	Teriparatide	T116,T121,T125	C0070093
27561345	104	128	1-34 parathyroid hormone	T116,T123	C1956225
27561345	150	160	treatments	T061	C0087111
27561345	165	177	osteoporosis	T047	C0029456
27561345	179	191	Teriparatide	T116,T121,T125	C0070093
27561345	201	216	anabolic effect	T039	C3179309
27561345	221	235	bone formation	T042	C0029433
27561345	250	259	increases	T169	C0442805
27561345	260	280	bone mineral density	T201	C0005938
27561345	292	302	prevention	T080	C2700409
27561345	306	315	fractures	T037	C0016658
27561345	331	341	population	T098	C1257890
27561345	395	404	effect of	T080	C1704420
27561345	405	417	teriparatide	T116,T121,T125	C0070093
27561345	421	429	increase	T169	C0442805
27561345	433	453	bone mineral density	T201	C0005938
27561345	457	468	maintenance	T052	C0024501
27561345	469	481	hemodialysis	T061	C0019004
27561345	482	490	patients	T101	C0030705
27561345	507	514	CKD-MBD	T047	C4076240
27561345	516	528	osteoporosis	T047	C0029456
27561345	550	562	pathological	T091	C0030664
27561345	563	569	change	T169	C0392747
27561345	573	577	ESRD	T047	C0022661
27561345	578	586	patients	T101	C0030705
27561345	602	608	safety	T062	C1705187
27561345	613	621	efficacy	T062	C1707887